A meta‑analysis compared CAR‑T cell therapy and bispecific antibody therapy for relapsed or refractory indolent B‑cell non‑Hodgkin’s lymphomas, synthesizing response and safety data across studies. The analysis highlights differences in efficacy metrics and toxicity profiles, offering clinicians data to weigh cellular therapy’s durable remissions against bispecifics’ off‑the‑shelf accessibility. The paper details rates of cytokine release syndrome, neurotoxicity, and overall response, and calls for randomized trials to define optimal sequencing. For readers: bispecifics redirect endogenous T cells to tumor antigens without ex vivo cell manufacture, unlike CAR‑T.